trending Market Intelligence /marketintelligence/en/news-insights/trending/3qgdjjrng-qvvmxmz3yihg2 content esgSubNav
In This List

Puma Biotechnology appeals EMA's negative opinion on breast cancer drug

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Puma Biotechnology appeals EMA's negative opinion on breast cancer drug

Puma Biotechnology Inc. appealed the rejection of its breast cancer drug in the EU.

The company asked for a re-examination of the European Medicines Agency's negative opinion on Nerlynx.

Nerlynx, or neratinib, is indicated as an extended additional cancer treatment for early-stage human epidermal growth factor receptor 2-positive breast cancer. Human epidermal growth factor receptor 2 is a type of protein involved in normal cell growth and can be found on some cancer cell types.

The committee previously rejected the company's application for the breast cancer drug, citing how the medicine's benefits did not outweigh its risks.